SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-071470
Filing Date
2023-03-15
Accepted
2023-03-15 17:20:54
Documents
12
Period of Report
2023-03-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 8-K d474257d8k.htm   iXBRL 8-K 25711
  Complete submission text file 0001193125-23-071470.txt   150836

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mtcr-20230315.xsd EX-101.SCH 2503
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mtcr-20230315_lab.xml EX-101.LAB 18783
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mtcr-20230315_pre.xml EX-101.PRE 11697
6 EXTRACTED XBRL INSTANCE DOCUMENT d474257d8k_htm.xml XML 3679
Mailing Address 4225 EXECUTIVE SQUARE SUITE 600 SAN DIEGO CA 92037
Business Address 4225 EXECUTIVE SQUARE SUITE 600 SAN DIEGO CA 92037 858-369-7800
Metacrine, Inc. (Filer) CIK: 0001634379 (see all company filings)

IRS No.: 472297384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39512 | Film No.: 23736218
SIC: 2834 Pharmaceutical Preparations